ARTICLE | Product Development Patient was in trial of the company’s limb-girdle muscular dystrophy gene therapyJuly 17, 2025 11:51 PM UTC A third patient, a 51 year-old in a Phase I study of SRP-9004 for Limb-Girdle muscular dystrophy Type 2E, has died from a Sarepta gene therapy.Like two deaths associated with the company’s Duchenne muscular dystrophy gene therapy, Elevidys delandistrogene moxeparvovec, the most recent death was caused by acute liver toxicity, Sarepta Therapeutics Inc. (NASDAQ...